

Letter to Our Stockholders

Dear Stockholders:

The NEXUS team was also able to show positive figures and promising developments in the third quarter 2015. This is a very pleasing result given the considerable investments, challenges and significant changes in recent months.

With an increase of approx. 24 % in sales and EBIT, our growth rate has continued combined with a continuous improvement in results. The initial consolidation of NEXUS Nederland for eight months had a significant share in this. On top of that, we were able to acquire very interesting new projects in 2015. We won new orders for total hospital solutions in Germany, Netherlands, France and Austria. We also received numerous orders in the diagnostic field, in particular in the areas of radiology (the new NEXUS / RIS) and cardiology (CWD – Clinic Win Data). We won interesting tenders in outsourcing area, and our expanded service offering is attracting growing interest among our customers.

The market environment, in which we operate so successfully, has shifted further in recent months. The strong supplier concentration has led to a general realignment of the competitive environment and is obviously still ongoing. Customers initially responded to these changes with uncertainty and reluctance to invest. However, there were initial indications in the third quarter that this phase is nearing its end.

We have used the last few months to implement four basic strategy projects. Our goal is to orient NEXUS to the changes in the market and accelerate our company's internationalization.

1. Entry into the Dutch market

We were able to acquire a strong company in the Dutch market with quCare B.V., Uetrecht. The company – which is now trading under the name of NEXUS Nederland – will become a complete provider of e-health solutions in the Netherlands thanks to the extension of the product range and the integration of NEXUS software modules. We will be able to offer administrative, clinical and diagnostic solutions from one source in the future.

Highlights 3rd Quarter 2015 – Company Development

- + Very strong sales growth in the first nine months
- + Acquisition of a Dutch HIS provider
- + Very promising collaboration with a medical device manufacturer
- Special acquisition and exchange rate-related factors
- + Reorganization of NEXUS Group into international subsidiaries

2. Implementation of a new product offensive

As part of a new product offensive, we aim to position NEXUS products on the market even more attractively. The core project is the implementation of an entirely new user interface within our product lines. We focus our screen layouts on the essential information in the work situation and thereby define a new way of operating clinical software. Connected with that, we are expanding our mobility concept "NEXUS / MOBILE" considerably and consequently designing the application of NEXUS / HIS to be increasing mobile. The automated and intelligent support of diagnostic processes within our product group "NEXUS / SPECIAL DIAGNOSTICS" is another innovation project, which is of great importance for the economic viability of hospitals and for the acceptance of users.

3. European-wide cooperation with medical device manufacturers

We have agreed on an entirely new way of opening up new markets with the medical device manufacturer Olympus Europe in the field of endoscopic documentation. In this technology partnership, the existing software of the existing endoscopic software of the endoscopy and OP specialists Olympus will be developed further jointly with NEXUS in the future. We have made considerable upfront investments in this project in recent months and are confident that this partnership will develop very successfully for both sides.

4. Reorganization of NEXUS Group

We have reorganized NEXUS Group to take advantage of future growth opportunities. The core of the reorganization is the establishment of subsidiaries in key markets. We are convinced that we can generate more growth with this transparent and result-responsible structure for our business.

NEXUS is increasingly positioning itself as a company operating in Europe and focusing further on growth with these strategic projects. We especially see considerable potential in international collaboration. We have development and sales locations in Germany, Switzerland, the Netherlands, France and Austria in the meantime. We are pursuing the goal of sharing expertise, software and procedures between markets intensively and adopting the "best practices" from the respective health systems. Our strong focus on innovation sets an important signal in the market at the same time. NEXUS does not focus on market consolidation, but instead relies completely on the development and improvement of its product position.

Dear Shareholders, we changed our company greatly and have grown significantly in the process during the first nine months of the current year. We have launched new products on the market, and their success is quite pleasing news. The integration of new businesses has been largely positive, and our collaboration with Olympus is very promising. However, we also know that our rapidly evolving business model faces challenges and risks. The goal to develop NEXUS into a leading European provider of e-health solutions remains a challenge. This is a challenge that we are glad to face.

We want to thank you, dear Shareholders, for your trust.

Warm regards,

Ingo Samanar.

Dr. Ingo Behrendt CEO



Financial Highlights for the 3rd Quarter 2015 and 2014

	30/09/2015	30/09/2014	Changes
	KEUR	KEUR	%
Sales	69,949	56,351	24.1
Healthcare Software Sales	64,189	49,883	28.7
Healthcare Service Sales	5,760	6,468	-10.9
Group result before interests and tax on income (EBIT)	6,341	5,134	23.5
Group result before interests	6,403	5,285	21.2
Consolidated Surplus	6,270	5,282	18.7
EBITA	8,674	6,389	35.8
EBITDA	13,382	10,038	33.3
Earnings per Share	0.40	0.37	8.1
Depreciation	7,041	4,904	43,6
Net Liquidity	18,082	26,145	-30.8
Cash Flow from current business transactions	13,823	7,799	77.2
Employees (as of the record date)	788	625	26.1

Interim Annual Report Report about the Profit, Financial and Asset Situation

NEXUS Group sales increased from KEUR 56,351 to KEUR 69,949 (+24.1 %) in the first nine months of the year 2015.

As a result, the sustained steady sales development of NEXUS Group of recent years could be continued. The decisive sales growth came from the area of Healthcare Software. Sales increased from KEUR 49,883 to KEUR 64,189 (+28.7 %) in this division. The Healthcare Service Division was able to achieve revenues of KEUR 5,760 compared to the first three quarters of 2014 of KEUR 6,468 (-10.9 %).

We were able to increase sales in Germany by 1.8 % to KEUR 34,239 (9M-2014: KEUR 33,650). In international business, we recorded sales of KEUR 35,710 in the first three quarters compared to KEUR 22,701 in the previous year (+57.3 %). The increase is due decisively to initial consolidation of NEXUS Nederland for the months February to September. We also had a significant sales increase in France, where we consolidated our subsidiary CS3I, Vichy. There were sales effects from exchange rate fluctuations of the Swiss franc in the amount of KEUR 2,059. The average exchange rate of the Swiss franc of SFR 1.08 on 30 September 2015 was below of the average price on 31 December 2014 (SFR 1.21).


The operating result before taxes and interest (EBIT) improved by 23.5 % to KEUR 6,341 (9M-2014: KEUR 5,134). EBITA (earnings before interest, taxes and acquisition-related amortization), which is becoming increasingly important for us, reached KEUR 8,674 in the first nine months and consequently was 35.8 % higher than the previous year (9M-2014: KEUR 6,389). EBITDA also rose significantly by 33.3 %. KEUR 13,382 was recorded here in the first nine months of 2015 (9M-2014: KEUR 10,038).

The cash flow from on-going business transactions developed positively. This reached a value of KEUR 13,823 and thus an increase of 77.2 % compared to the previous year (9M-2014: KEUR 7,799). The reasons for this are the higher advance payments for maintenance and active accounts receivable management.


Consolidated net income amounted to KEUR 6,270 (9M-2015) and thus increased by 18.7 % over the prior year value of KEUR 5,282. Earnings per share also evolved upwards and amounted to EUR 0.40 (9M-2014: EUR 0.37).

Cash and cash equivalents including securities amounted to KEUR 18,082 on 30 September 2015 (31 December 2014: KEUR 22,578).

Group sales (9 months) in KEUR +24.1 % as of previous year



Profit before interest and tax (9 months) in KEUR +23.5 % as of previous year



Investments in tangible and intangible assets were made in the amount of KEUR 6,640 in the first nine months (9M-2014: KEUR 4,521). This includes KEUR 1,300 for the acquisition of land and buildings. NEXUS is investing in a new headquarters, which we expect to move into at the beginning of 2016.

A total of KEUR 17,782 was invested in the first nine months of 2015 for the acquisition of the quCare Group, Utrecht, Netherlands, and for payment of residual purchase price claims from previous acquisitions after deduction of cash acquired.

The balance sheet total increased from KEUR 108,189 (31 December 2014) to KEUR 130,057. There are no essential bank liabilities. Intangible assets, goodwill and net deferred taxes add up to a total of KEUR 74,864 following KEUR 57,283 (31 December 2014). Receivables from customers increased slightly from KEUR 19,275 (31 December 2014) to KEUR 20,302.

Capital

The Executive Board of NEXUS AG decided on 26 February 2015 on a capital increase with the consent of the Supervisory Board for partial refinancing of acquisitions made over the past few months. Using the authorized capital available, the capital stock of NEXUS AG was increased by EUR 630,515 (4.2 %) from the previous EUR 15,105,150 to EUR 15,735,665 against cash investment via issue of 630,515 registered shares with exclusion of subscription rights. Thanks to the placement of new shares among investors, 8.8 million euros gross were taken in. The issue price was 13.95 euros. By resolution of the general stockholders meeting on 18 May 2015 NEXUS paid a dividend of EUR 0.13 per share for the business year 2014.

Financial Highlights 3rd Quarter 2015

- + 24.1 % increase in sales from KEUR 56,35 (9M-2014) to KEUR 69,949 (9M-2015)
- + 23.5 % increase in EBIT from KEUR 5,134 (9M-2014) to KEUR 6,341 (9M-2015)
- + 35.8 % increase in EBITA from KEUR 6,389 (9M-2014) to KEUR 8,674 (9M-2015)
- + 77.2 % increase of operating cash flow from KEUR 7,799 (9M-2014) to KEUR 13,823 (9M-2015)

Employees

NEXUS Group employed a total of 788 people as of 30 September 2015 (30 September 2014: 625 employees). A total of 726 employees (30 September 2014: 563) are employed in the Healthcare Software Division. The Healthcare Service Division employed 62 people (30 September 2014: 62).


Sales by division

	01/01/ - 30/09/15	01/01/ - 30/09/14	Changes	01/07/ - 30/09/15	01/07/ - 30/09/14	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Healthcare Software	64,189	49,883	28.7	20,735	16,281	27.4
Healthcare Service	5,760	6,468	-10.9	2,163	2,247	-3.7
Total	69,949	56,351	24.1	22,898	18,528	23.6

Sales by region

	01/01/ - 30/09/15	01/01/ - 30/09/14	Changes	01/07/ - 30/09/15	01/07/ - 30/09/14	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	34,239	33,650	1.8	10,975	11,274	-2.7
Switzerland	19,259	19,039	1.2	6,471	6,549	-1.2
Netherlands	10,589	0	> 100	3,813	0	> 100
France	3,959	1,202	> 100	1,249	62	> 100
Austria	1,216	1,182	2.9	282	305	-7.5
Other countries	687	1,278	-46.2	108	338	-67.9
Total	69,949	56,351	24.1	22,898	18,528	23.6

SIMPLY BETTER



NEXUS / NEXT GENERATION Experience a new KIS generation www.nexus-ag.de



NEXUS Group Information and Outlook

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2014 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Outlook: Develop in a Targeted Manner

We are again very satisfied with the first nine months in 2015. Sales and result before interest and taxes each rose by approx. 24 %, and our operating cash flow reached approx. \in 13.8 million compared to \in 7.8 million in the same period last year. As a result, we have been able to confirm the prevailing positive trend of recent years both in sales and result. The initial consolidation of NEXUS Nederland sales for eight months and the favourable development for NEXUS of the exchange rate of the Swiss franc helped to achieve this strong figures. The special charges related to the acquisition and integration of businesses are also fully integrated in the result.

In addition to the positive figures, we are also on the right path in terms of our corporate goal. As a company operating in Europe, our decentralized teams share their knowledge, technologies, employees and products. In this way, the experience and strengths in the different healthcare systems are combined and product innovations are accelerated significantly. We are positioning ourselves in this way as a strong European e-health company that has a clear technology and growth strategy. Consequently, our further development is clearly defined. It is an ambitious undertaking, and we will need to show that we can deal with the significant challenges associated with it in the manner that has been successful until today.

Accounting and Valuation Methods

Directors' Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 30 September 2015 in comparison to the previous year: cf. Table.

Superviory Board	Numbers of stock owned	Numbers of options
Dr. jur. Hans-Joachim König	89,900 Previous year (101,239)	0 Previous year (0)
Prof. Dr. Alexander Pocsay	121,500 Previous year (121,500)	0 Previous year (0)
Gerald Glasauer	0 Previous year (-)	0 Previous year (-)
Prof. Dr. Ulrich Krystek	0 Previous year (0)	0 Previous year (0)
Wolfgang Dörflinger	0 Previous year (0)	0 Previous year (0)
Prof. Dr. med. Felicia M. Rosenthal	0 Previous year (-)	0 Previous year (-)

Executive Board	Numbers of stock owned	Numbers of options
Dr. Ingo Behrendt	112,000 Previous year (112,000)	0 Previous year (0)
Ralf Heilig	135,350 Previous year (135,350)	0 Previous year (0)
Edgar Kuner	248,051 Previous year (248,051)	0 Previous year (0)

This interim report from the NEXUS Group of 30 September 2015 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 September 2015. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2014. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2014.

The report has not been audited.

The Annual Report 2014 and Quarterly Report as of 30 September 2015 could be downloaded on www.nexus-ag.de

Capital market, event and finance data

Investor Relations

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via telephone conferences, oneon-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.



Frankfurt Stock Exchange stock prices (1-year period)

Stock Market Highlights (XETRA prices)

- + Initial listing o
- 2 January 2015: € 11.87
- 30 September 2015: € 18.55
- + Stock Market Price on 30 September 2015: € 17.90
- + Stock market capitalization of 30 September 2015:
 € 281.7 million

26/11 - 29/11/2015 Fortbildungstagung Klinische Zytologie, München

01/12 - 03/12/2015 27. Deutscher Kongress für Perinatale Medizin, Berlin

02/12 - 04/12/2015 DIVI-Kongress für Intensiv- und Notfallmedizin, Leipzig

21/01 - 23/01/2016 CT Symposium, Garmisch-Partenkirchen **29/01 - 31/01/2016** Bamberger Morphologietage, Bamberg

29/02 - 02/03/2016 Reha-Kolloquium, Aachen

29/02 - 04/03/2016 HIMSS, Las Vegas (USA)

08/03 - 10/03/2016 Altenpflege, Hannover **23/11 - 25/11/2015** German Equity Forum, Frankfurt

22/03/2016 Publishing Annual Report 2015

More IR events for the year 2016 will be announced with the release of the financial report 2015.

Consolidated Profit and Loss Account as of 30/09/2015 and 30/09/2014

	01/01/- 30/09/2015	01/01/- 30/09/2014	01/07/- 30/09/2015	01/07/- 30/09/2014
	KEUR	KEUR	KEUR	KEUR
Revenue	69,949	56,351	22,898	18,528
Development work capitalized	3,542	3,045	1,145	946
Other operating income	1,620	1,258	258	704
Cost of materials including purchased services	10,975	10,400	3,779	3,442
Personnel costs	41,154	31,993	13,400	10,700
Depreciation	7,041	4,904	2,402	1,587
Other operating expenses	9,599	8,223	2,662	2,986
Operating Result	6,341	5,134	2,057	1,463
Result from investments valuated at equity	0	49	0	49
Finance Income	86	130	8	26
Finance Expenses	24	28	12	5
Result before Tax on Profit	6,403	5,285	2,053	1,533
Taxes on profit	133	3	178	-37
Consolidated Surplus	6,270	5,282	1,875	1,570
of the consolidated surplus, accounted to: - Stockholders of NEXUS AG - Shares of non-controlling partners	6,275 -5	5,515 -233	1,848 27	1,719 -59
Consolidated surplus per share in EUR				
Weighted average of issued shares in circulation (in thousands) - Simple - Diluted	15,645 0.40 0.40	15,069 0.37 0.37	15,610 0.12 0.12	15,069 0.11 0.11

Consolidated Income Statement as of 30/09/2015 and 30/09/2014

01/01/- 30/09/2015	01/01/- 30/09/2014	01/07/- 30/09/2015	-/01/07 30/09/2014
KEUR	KEUR	KEUR	KEUR
6,270	5,282	1,875	1,570
-309	-437	365	-5
44	0	-52	0
1,192	595	-1,293	-39
927	158	-980	-44
7,197	5,440	895	1,526
7,202	5,673	868	1,585
-5	-233	27	-59
	30/09/2015 KEUR 6,270 -309 44 1,192 927 7,197 7,202	30/09/2015 30/09/2014 KEUR KEUR 6,270 5,282 -309 -437 44 0 1,192 595 927 158 7,197 5,440 7,202 5,673	30/09/2015 30/09/2014 30/09/2015 KEUR KEUR KEUR 6,270 5,282 1,875 -309 -437 365 44 0 -52 1,192 595 -1,293 927 158 -980 7,197 5,440 895 7,202 5,673 868

Consolidated Balance Sheet as of 30/09/2015 and 31/12/2014

Assets	30/09/2015	31/12/2014
	KEUR	KEUR
Long-Term Assets		
Goodwill	39,730	27,976
Other intangible assets	35,813	27,996
Fixed assets	4,364	2,241
Shares in companies valuated at equity	30	34
Differed tax assets	5,058	4,828
Other financial assets	213	400
Total of Long-Term Assets	85,208	63,475
Short-Term Assets		
Inventories	880	589
Trade receivables and other receivables	20,302	19,275
Receivables from tax on profits	1,275	675
Other non-financial assets	2,211	1,029
Other financial assets	2,099	568
Short-term financial assets	3,147	9,218
Cash and balance in bank	14,935	13,360
Total of Short-Term Assets	44,849	44,714
Total Assets	130,057	108,189

Equity and Liabilities	30/09/2015	31/12/2014	
	KEUR	KEUR	
Equity Capital			
Authorized capital	15,736	15,105	
Capital reserves	33,799	25,980	
Profit carried forward	37,034	30,705	
Consolidated surplus	6,275	8,279	
Other cumulated Group result	-2,147	-3,074	
Own shares	-272	-280	
Equity Capital Attributable to Stockholders of the Parent Company	90,425	76,715	
Shares of non-controlling partners	-782	-903	
Total Equity Capital	89,643	75,812	
Long-Term debts			
Pension obligations	8,065	5,987	
Deferred tax liabilities	5,737	3,517	
Financial liabilities	0	15	
Other financial depts	1,247	2,288	
Total of Long-Term Debts	15,049	11,807	
Short-Term Debts			
Accruals	895	1,291	
Financial liabilities	15	253	
Trade accounts payable	3,858	4,890	
Liabilities from tax on profit	1,888	996	
Deferred revenue	9,246	985	
Other non-financial debts	6,780	4,991	
Other financial debts	2,683	7,164	
Total of Short-Term Debts	25,365	20,570	
Balance Sheet Total	130,057	108,189	

16,574

Consolidated Cash Flow Statement for the period from 01/01/ to 30/09/2015 and 2014

	2015	2014
	KEUR	KEUR
1. Cash Flow from Current Business Transactions		
Group result before tax on income	6,403	5,285
Write-offs (+) / write-ups (-) on intangible assets, property, plant and equipment	7,041	4,904
Other expenses (+) / income (-)	1,133	-268
Increase (-) / decrease (+) in inventories	-291	-164
Gain (-) / loss (+) on the disposal of fixed assets and securities	32	0
Increase (-) / decrease (+) in receivables and other assets from operating activities	2,792	1,425
Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income	-396	779
Increase (+) / decrease (-) in liabilities from operating activities	-2,544	-4,030
Interest paid (-)	-24	-28
Interest received (+)	89	147
Income taxes paid (-)	-747	-282
Income taxes received (+)	335	31
Total	13,823	7,799
Cash Flow from Investment Activities Disbursements (-) for investments in intangible and fixed assets Disbursements (-) for the acquisition of consolidated companies minus cash acquired	-6,640	-4,521
Disbursements (-) for the acquisition of consolidated companies minus cash acquired	-13,995	-416
Disbursements (-) / proceeds (+) from the purchase / disposal of short-term financial assets	6,000	0
Total	-14,635	-4,937
3. Cash Flow from Financing Activities		
Proceeds (+) from increase of capital stock	8,597	0
Dividends paid (-)	-1,961	-1,808
Payments (-) for the acquisition of non-controlling interests for already consolidated companies	-3,787	0
Receipts (+) from the sale of own shares	59	53
Total	2,908	-1,755
Cash and cash equivalents at beginning of period	13,107	15,467
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	2,096	1,107
Change in cash and cash equivalents resulting from exchange rates	-268	0
Cash and cash equivalents at end of period	14,935	16,574
Composition of cash and cash equivalents		
Liquid Funds	14,935	16,955
Bank liabilities due on demand	0	-381

 Total
 14,935

Statement of Changes in Consolidated Equity as of 30/09/2015 and 30/09/2014

	X CD Subscribed capital	X Capital reserves	 Equity capital difference from currency conversion 	X Annotations provisions	H D B D Profit carried forward	A Annual Net Profit	Own Shares	H Equity capital attributable C to stock of parent company	A Shares of non-controlling C partners	A Capital total B	A C Authorized Capital
Consolidated Equity as of 01/01/2014	15,105	25,780	504	-1,592	25,293	7,221	-290	72,021	-526	71,495	6,353
Posting of the consolidated profit 2013 in the Group profit carried forward					7,221	-7,221		0		0	
Total of the result entered directly into equity capital			595	-437				579		579	
Other Comprehensive Income After Taxes 30/09/2014	0	0	595	-437	7,221	-7,221	0	579	0	579	0
Consolidated surplus 9M-2014						5,515		5,515	-233	5,282	
Overall Result of the Period	0	0	595	-437	7,221	-1,706	0	6,094	-233	5,861	0
Dividend payment					-1,808			-1,808		-1,808	
Purchase/sale of own shares		24					4	28		28	
Consolidated Equity as of 30/09/2014	15,105	25,804	1,099	-2,029	30,706	5,515	-286	76,335	-759	75,576	6,353
Consolidated Equity as of 01/01/2015	15,105	25,980	897	-3,971	30,705	8,279	-280	76,715	-903	75,812	6,353
Posting of consolidated surplus 2014 in the Group loss carried forward					8,279	-8,279		0		0	
Actuarial profits and losses				-309				-309		-309	
Deferred taxes entered in other comprehensive income				44				44		44	
Currency exchange differences			1,192		11			1,203	-24	1,179	
Other Comprehensive Income After Taxes 30/09/2015	0	0	1,192	-265	8,290	-8,279	0	938	-24	914	0
Consolidated surplus 9M-2015						6,275		6,275	-5	6,270	
Overall Result of the Period	0	0	1,192	-265	8,290	-2,004	0	7,213	-29	7,184	0
Dividend payment					-1,961			-1,961		-1,961	
Purchase/sale of own shares		51					8	59		59	
Capital Increase	631	7,966						8,597		8,597	-631
Change in capital reserves		-198						-198	150	-48	
Consolidated Equity as of 30/09/2015	15,736	33,799	2,089	-4,236	37,034	6,275	-272	90,425	-782	89,643	5,722

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, 10 November 2015

NEXUS AG The Executive Board



NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen Telefon +49 (0)7721 8482-0, Fax +49 (0)7721 8482-888 www.nexus-ag.de, info@nexus-ag.de